Solid 1996 Earnings Growth At Synthelabo

10 March 1997

French pharmaceutical group Synthelabo achieved group net profits in1996 of 950.7 million French francs ($168.2 milion), an increase of 19.7%, and earnings per share grew 19.7% to 19.69 francs. Operating profits were ahead 24.8% to 1.52 billion francs.

The firm said that the 24.8% rise in operating profits, after a portion reverted to its joint-venture partner Searle, reflects the growth in sales and an improvement in gross margin related to a strong performance by its strategic products, especially Ambien/Stilnox (zolpidem) in the USA.

Synthelabo posted its sales figures for 1996 in January (Marketletter January 27). Turnover for the year was up 11.3% to 10.4 billion francs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.